MeSH D000755 - sickle cell anemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Global Blood Therapeutics | Voxelotor | Oxbryta | 2032-12-28 | 2019-11-25 |  |  |
| Nova Laboratories | Hydroxycarbamide | Xromi |  | 2019-07-01 |  |  |
| Novartis | Crizanlizumab | Adakveo |  | 2020-10-28 | $165 M | Q2/20-Q2/23 |
| Pfizer | Voxelotor | Oxbryta |  | 2022-02-14 | $328 M | Y2023 |
| Vertex Pharmaceuticals | Exagamglogene autotemcel | Casgevy |  | 2023-12-08 | $2 M | Y2024 |
Clinical Trials
Historical Success Rate
Phase 1
69%71/103
Phase 2
38%46/121
Phase 3
39%19/49
Approved: 5Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use